Early effects of low molecular weight heparin therapy with soft-mist inhaler for COVID-19-induced hypoxemia: a phase iib trial

Basit Öğe Kaydı
dc.authoridAybige Ertürk / 0000-0002-5179-5865
dc.authorscopusidAybige Ertürk / 57312790100en_US
dc.authorwosidAybige Ertürk / GAQ-1057-2022
dc.contributor.authorErelel, Mustafa
dc.contributor.authorKaskal, Mert
dc.contributor.authorAkbal-Dağıstan, Özlem
dc.contributor.authorİşsever, Halim
dc.contributor.authorErtürk, Aybige
dc.date.accessioned2021-11-08T07:14:55Z
dc.date.available2021-11-08T07:14:55Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümüen_US
dc.description.abstractIn COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.en_US
dc.identifier.citationErelel M, Kaskal M, Akbal-Dagistan O, Issever H, Dagistanli AS, Balkanci H, Oguz MS, Qarayeva A, Culha M, Erturk A, Basarir NS, Sahin G, Uresin AY, Araman AO, Medetalibeyoglu A, Tukek T, Oncul MO, Yildiz-Pekoz A. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics. 2021; 13(11):1768. https://doi.org/10.3390/pharmaceutics13111768en_US
dc.identifier.doi10.3390/pharmaceutics13111768en_US
dc.identifier.endpage13en_US
dc.identifier.issn1999-4923en_US
dc.identifier.issue11en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics13111768
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2200
dc.identifier.volume13en_US
dc.identifier.wosWOS:000727143300001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorErtürk, Aybige
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofPharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-coagulanen_US
dc.subjectCOVID-19en_US
dc.subjectLow-Molecular-Weight Heparinen_US
dc.subjectPulmonaryen_US
dc.subjectSoft-mist İnhaleren_US
dc.titleEarly effects of low molecular weight heparin therapy with soft-mist inhaler for COVID-19-induced hypoxemia: a phase iib trialen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
226.pdf
Boyut:
858.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Teknolojisi Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu